|
1
|
Geng Y, Michowski W, Chick JM, Wang YE,
Jecrois ME, Sweeney KE, Liu L, Han RC, Ke N, Zagozdzon A, et al:
Kinase-independent function of E-type cyclins in liver cancer. Proc
Natl Acad Sci USA. 115:1015–1020. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fu M, Shi W, Li Z and Liu H: Activation of
mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC
inhibitor resminostat in hepatocellular carcinoma cells. Biochem
Biophys Res Commun. 477:527–533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang J, Jin X, Yan Y, Shao Y, Pan Y,
Roberts LR, Zhang J, Huang H and Jiang J: Inhibiting histone
deacetylases suppresses glucose metabolism and hepatocellular
carcinoma growth by restoring FBP1 expression. Sci Rep.
7:438642017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen T, Gu C, Xue C, Yang T, Zhong Y, Liu
S, Nie Y and Yang H: LncRNA-uc002mbe.2 interacting with hnRNPA2B1
Mediates AKT deactivation and p21 Up-regulation induced by
trichostatin in liver cancer cells. Front Pharmacol. 8:6692017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
West AC and Johnstone RW: New and emerging
HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J and Zhong Q: Histone deacetylase
inhibitors and cell death. Cell Mol Life Sci. 71:3885–3901. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L
and Wu MC: Inhibition of autophagy signi fi cantly enhances
combination therapy with sorafenib and HDAC inhibitors for human
hepatoma cells. World J Gastroenterol. 20:4953–4962. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoon CY, Park MJ, Lee JS, Lee SC, Oh JJ,
Park H, Chung CW, Abdullajanov MM, Jeong SJ, Hong SK, et al: The
histone deacetylase inhibitor trichostatin A synergistically
resensitizes a cisplatin resistant human bladder cancer cell line.
J Urol. 185:1102–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li YL, Zhang NY, Hu X, Chen JL, Rao MJ, Wu
LW, Li QY, Zhang B, Yan W and Zhang C: Evodiamine induces apoptosis
and promotes hepatocellular carcinoma cell death induced by
vorinostat via downregulating HIF-1α under hypoxia. Biochem Biophys
Res Commun. 498:481–486. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang GW, Yang LY and Lu WQ: Expression of
hypoxia-inducible factor 1alpha and vascular endothelial growth
factor in hepatocellular carcinoma: Impact on neovascularization
and survival. World J Gastroenterol. 11:1705–1708. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ellinghaus P, Heisler I, Unterschemmann K,
Haerter M, Beck H, Greschat S, Ehrmann A, Summer H, Flamme I, Oehme
F, et al: BAY 87-2243, a highly potent and selective inhibitor of
hypoxia-induced gene activation has antitumor activities by
inhibition of mitochondrial complex I. Cancer Med. 2:611–624.
2013.PubMed/NCBI
|
|
12
|
Schöckel L, Glasauer A, Basit F, Bitschar
K, Truong H, Erdmann G, Algire C, Hägebarth A, Willems PH, Kopitz
C, et al: Targeting mitochondrial complex I using BAY 87-2243
reduces melanoma tumor growth. Cancer Metab. 3:112015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basit F, van Oppen LM, Schöckel L,
Bossenbroek HM, van Emst-de Vries SE, Hermeling JC, Grefte S,
Kopitz C, Heroult M, Hgm Willems P and Koopman WJ: Mitochondrial
complex I inhibition triggers a mitophagy-dependent ROS increase
leading to necroptosis and ferroptosis in melanoma cells. Cell
Death Dis. 8:e27162017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Helbig L, Koi L, Brüchner K, Gurtner K,
Hess-Stumpp H, Unterschemmann K, Baumann M, Zips D and Yaromina A:
BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation,
improves local tumor control after fractionated irradiation in a
schedule-dependent manner in head and neck human xenografts. Radiat
Oncol. 9:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Häcker G: The morphology of apoptosis.
Cell Tissue Res. 301:5–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lan Y, Han J, Wang Y, Wang J, Yang G, Li
K, Song R, Zheng T, Liang Y, Pan S, et al: STK17B promotes
carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in
hepatocellular carcinoma. Cell Death Dis. 9:2362018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen
L, Zhu YH, Li J, Li Y, Ma S, et al: Maelstrom promotes
hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail
signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peinado H, Portillo F and Cano A:
Switching on-off Snail: LOXL2 versus GSK3beta. Cell Cycle.
4:1749–1752. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cassim S, Raymond VA, Dehbidi-Assadzadeh
L, Lapierre P and Bilodeau M: Metabolic reprogramming enables
hepatocarcinoma cells to efficiently adapt and survive to a
nutrient-restricted microenvironment. Cell Cycle. 17:903–916. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amann T, Maegdefrau U, Hartmann A, Agaimy
A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich
J, Oefner PJ, et al: GLUT1 expression is increased in
hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol.
174:1544–1552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kitajima Y and Miyazaki K: The critical
impact of HIF-1a on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hall JL, Chatham JC, Eldar-Finkelman H and
Gibbons GH: Upregulation of glucose metabolism during intimal
lesion formation is coupled to the inhibition of vascular smooth
muscle cell apoptosis. Role of GSK3beta. Diabetes. 50:1171–1179.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu KY, Wang LT and Hsu SH: Modification
of epigenetic histone acetylation in hepatocellular carcinoma.
Cancers (Basel). 10(pii): E82018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin KT, Wang YW, Chen CT, Ho CM, Su WH and
Jou YS: HDAC inhibitors augmented cell migration and metastasis
through induction of PKCs leading to identification of low toxicity
modalities for combination cancer therapy. Clin Cancer Res.
18:4691–4701. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu W, Liu H, Liu ZG, Wang HS, Zhang F,
Wang H, Zhang J, Chen JJ, Huang HJ, Tan Y, et al: Histone
deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation
and stabilization of Snail to promote metastasis of hepatoma cells.
Cancer Lett. 420:1–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
